Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Leucovorin Calcium Market size was over USD 26.98 million in 2024 and is poised to exceed USD 187.87 million by 2037, witnessing over 16.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of leucovorin calcium is estimated at USD 34.38 million.
The growth of this market can be attributed to the growing presence of cancer patients globally. Leucovorin calcium is widely used to treat cancer patients in the chemotherapy process it is used as an effective drug in the treatment. In 2020, around 20 million cancer cases were recorded all over the world.
Rising blood cells disorder such as anemia, thrombocytopenia, and neutropenia that is caused by high doses of an antagonist such as methotrexate, trimethoprim, and pyrimethamine are significant factor anticipated to drive the industry growth. In addition, growing cases of megaloblastic anemia caused by folic acid deficiency are expected to drive the market growth of the leucovorin calcium market in the forecast period. Leucovorin calcium is used to treat megaloblastic anemia in cases when oral therapy is not feasible. About 1 in 7.5 thousand people develop megaloblastic anemia in the United States every year.
Leucovorin Calcium Sector: Growth Drivers & Challenges
Growth Drivers
- Increasing Prevalence of Colon-Rectal Cancer – Leucovorin calcium is a medication commonly used as rescue therapy in combination with fluorouracil to treat colon and rectal cancer. This drug helps improve the efficacy of fluorouracil and reduce its toxicity. The increasing prevalence of colorectal cancer is a significant driver of the leucovorin market as leucovorin is an integral part of chemotherapy regimens for the disease. In 2020, 1 million cases of colon rectal cancer were recorded in the United States.
- Growing Cancer Awareness amongst People –Increasing awareness of cancer amongst the general population is a key factor driving the market. As people become more aware of the signs and symptoms of cancer and the importance of early detection, they are more likely to see a doctor and receive appropriate treatment, including the use of leucovorin calcium. More than 40% population gets diagnosed with cancer at an early stage.
- Growing Prevalence of Megaloblastic Anemia – When oral medication is not an option, leucovorin calcium is used to treat megaloblastic anemia, and is further anticipated to fuel market expansion over the forecast period. Additionally, folic acid or vitamin B12 deficiency may result in megaloblastic anemia. Leucovorin calcium, aids in the restoration of normal cell division and maturation by giving the body a source of folic acid which can be used to create new red blood cells, further being a key medication in the treatment of megaloblastic anemia. Around 1.4% cases of megaloblastic anemia cases are caused by B12 deficiency.
- Growing Prevalence of Cancer in Developed and Developing Countries – Rising presence of cancer among people situated in developed and developing countries is anticipated to propel the growth of this market in the forecast period. In developed countries, cancer rates are high owing to factors such as increased life expectancy and the adoption of unhealthy lifestyles. As developing countries undergo rapid industrialization and modernization, cancer rates are also increasing, leading to lifestyle changes and exposure to environmental risk factors. Leucovorin calcium is commonly used as a component of chemotherapy regimens for many types of cancer, including colon, stomach, and ovarian cancer. For instance, according to studies 225,800 new cases of cancer were recorded in Canada in 2020.
Challenges
- Non-compatibility with other Drugs – Leucovorin calcium has some compatibility problems with various drugs such as capecitabine, and cotrimoxazole and also, leucovorin calcium reacts with breastfeeding, pregnant women, children, people with seizer problems, and geriatric population undergoing this medication must be kept under special monitoring. This factor might restrict the market to growth in the forecast period.
- High Cost Associated with Cancer Treatment
- Side Effects of Cancer Treatment Drugs
Leucovorin Calcium Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
16.1% |
|
Base Year Market Size (2024) |
USD 26.98 million |
|
Forecast Year Market Size (2037) |
USD 187.87 million |
|
Regional Scope |
|
Leucovorin Calcium Segmentation
End-user (Hospital, Retail Pharmacies, Specialty Clinics)
The global leucovorin calcium market is segmented and analyzed for demand and supply by end users into hospitals, retail pharmacies, specialty clinics, and others. Out of these, the hospital segment is anticipated to hold the largest market share by the end of 2037. The expansion of the healthcare system and the fact that the drug is not widely accessible and must be purchased with a prescription from a doctor both contribute to the market's growth. Also, the presence of growing cases of cancer and critical blood cell disorder raises the demand for the hospital segment globally. For instance, 1.25 million new instances of blood cancer, or about 6% of all cancer cases, are recorded annually. Leucovorin calcium is typically used for the treatments such as Hodgkin's lymphoma, ovarian cancer, colorectal cancer, and brain tumors. Leucovorin calcium has been used more frequently in hospital pharmacies as a result of its expanding potential for treating various malignancies, particularly colon cancer.
Route of Administration (Oral, Injectable)
The global leucovorin calcium market is segmented and analyzed for demand and supply by route of administration into oral, injectable, and others. Out of these, the injectable segment is anticipated to hold the largest market share by the end of 2037. Leucovorin is a medicine that consists of an active ingredient named leucovorin. It appears in injection form for application by intravenous infusion, intramuscularly into the under the skin of the stomach, muscle, or arm. The injection is found at API with sodium chloride, water for injection, and sodium hydroxide, or hydrochloric acid as a buffer.
Our in-depth analysis of the global market includes the following segments:
|
By Route of Administration |
|
|
By End User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Leucovorin Calcium Industry - Regional Synopsis
North American Market Forecast
North America industry is set to hold largest revenue share by 2037. This can be attributed owing to the presence of major pharmaceutical companies in the region backed by the high healthcare expenditure in the developed countries. As per the data by the U.S. Centers for Medicare & Medicaid Services, the national healthcare expenditure grew by 9.7% to USD 4.1 trillion in 2020. Owing to the presence of significant important companies and advanced healthcare infrastructure in the area, North America is anticipated to hold the biggest market share. Also, a rising number of people with blood disorders and colorectal cancer patients are boosting the region's leucovorin calcium market.
Europe Market Forecast
The market in the Europe region is estimated to witness noteworthy growth by the end of 2037. This can be attributed to the growing prevalence of cancer, along with the efficient healthcare system in the region. Europe is one of those countries in the world that has favorable health care policies and also has enhanced health care practices for the treatment of cancer. Countries such as Germany, and the UK have favorable reimbursement policies and established regulatory frameworks, they focus on patient safety, constantly monitor patients' health while the treatment is going on, and also treatment efficiency standards are high level these are a few significant factors that are estimated to drive the market growth.
APAC Market Statistics
The market in the Asia Pacific region is also anticipated to hold a significant market share by the end of 2037. Geriatric population growth; infrastructural improvements in the healthcare sector; and an increase in R&D activity in Asia-Pacific developing countries. Increasing product recalls since leucovorin calcium-drug interactions and supply problems as a result of restrictions on the import of raw materials into the United States, China, and India are a few of the challenges facing the worldwide leucovorin calcium market. Throughout the forecast period, an increase in launch prices is anticipated to present growth prospects for businesses active in this market. Moreover, the market is also expected to grow with the improving healthcare infrastructure in the region and growing awareness about cancer disease, its causes, and its treatment options in the region.
Companies Dominating the Leucovorin Calcium Landscape
- Exelixis Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- PromoCell GmbH
- Thermo Fisher Scientific Inc.
- Boehringer Ingelheim GmbH
- Bayer AG
- Abbott Laboratories
- Merck & Co., Inc.
- Mylan N.V.
- Novartis International AG
- Pfizer Inc.
Recent Developments
- Exelixis Inc. announced the successful results for Cabozantinib in combination with immunotherapies in patients with advanced colorectal cancer.
- PromoCell GmbH to lead research on immunotherapies through all human primary cells and blood & stem cells, including MHC class I genes HLA-A, -B, and -C.
Author Credits: Radhika Pawar
- Report ID: 4020
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
